Original Article

Hepcidin-orchestrated Hemogram and Iron Homeostatic Patterns in Two Models of Subchronic Hepatic injury

Ibtsam GHEITH¹ and Abubakr EL-MAHMOUDY², #

1. Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Taibah University, 344 Medinah, KSA; and Department of Biotechnology, Animal Health Research Institute, 11843 Dokki, Egypt; 2. Department of Pharmacology, Benha University Faculty of Vet. Medicine, 13736 Moshtohor, Qalioubeya, Egypt

Abstract

Objective This study was designed to evaluate hematological disorders and the orchestrating roles of hepcidin and IL-6 in rat models of thioacetamide (TAA) and carbon tetrachloride (CCl₄) hepatotoxicity.

Methods Rats were intraperitoneally injected with TAA (10 mg/100 g rat weight dissolved in isosaline) or CCl₄ (100 μL/100 g rat weight diluted as 1:4 in corn oil) twice weekly for eight consecutive weeks to induce subchronic liver fibrosis. Blood and tissue samples were collected and analyzed.

Results CCl₄ but not TAA significantly decreased the RBCs, Hb, PCV, and MCV values with minimal alterations in other erythrocytic indices. Both hepatotoxins showed leukocytosis, granulocytosis, and thrombocytopenia. By the end of the experiment, the erythropoietin level increased in the CCl₄ model. The serum iron, UIBC, TIBC, transferrin saturation%, and serum transferrin concentration values significantly decreased, whereas that of ferritin increased in the CCl₄ model. TAA increased the iron parameters toward iron overload. RT-PCR analysis revealed increased expression of hepatic hepcidin and IL-6 mRNAs in the CCl₄ model and suppressed hepcidin expression without significant effect on IL-6 in the TAA model.

Conclusion These data suggest differences driven by hepcidin and IL-6 expression between CCl₄ and TAA liver fibrosis models and are of clinical importance for diagnosis and therapeutics of liver diseases.

Key words: Anemia; Iron; Liver; Fibrosis; Hepcidin; IL-6

INTRODUCTION

Hepcidin is a small peptide that is synthesized by the liver and considered the main regulator of iron homeostasis. The expression of hepcidin in hepatocytes is induced by inflammatory generators, and it is considered an acute phase protein[1]. Hepcidin is a negative regulator of iron uptake in the small intestine and of iron release from macrophages. Hepcidin binds to ‘ferroportin’, the iron exporter protein; the binding results in the internalization and degradation of the transporter, thereby blocking the iron export from enterocytes and macrophages to the circulation[2]. Proinflammatory cytokines (IL-6, in particular) induce the expression and synthesis of hepcidin, causing iron deficiency anemia associated with inflammation and inflammatory diseases[3].

Injury of the liver, as any organ, results in a wound healing response that occurs in the liver tissue in the form of fibrosis[4]. Iredale[5] reviewed liver fibrosis models with differences that could be
considered as advantages and/or disadvantages. The availability of animal models is essential for study of the pathology and pharmacology of hepatic diseases. Models of subchronic/chronic liver injury may be induced by many stressors, such as drugs, hepatotoxins, nutrient stressors, immunological agents, metabolic modifiers, or genetic stressors\(^6\). Among the models, hepatotoxins, such as carbon tetrachloride (CCl\(_4\)) and thioacetamide (TAA), are the most specific for the liver and commonly used to induce subchronic/chronic liver injury. Both agents can induce apoptosis at low doses and necrosis at high doses (300 to 1,000 \(\mu\)L/Kg for CCl\(_4\) and 100 to 300 mg/Kg for TAA; ip, twice weekly) and react with hepatic macromolecules to induce oxidative stress, which may have carcinogenic effects on the long run\(^7\).

CCl\(_4\) should be metabolically activated in the liver to induce damage and is converted into trichloromethyl radical (CCl\(_3\)•) by cytochrome P450 oxidase system (CYP2E1). In the presence of oxygen, the CCl\(_3\)• radical is then converted into the highly reactive trichloromethylperoxy radical (CCl\(_3\)OO•), which initiates hepatocyte membrane lipid peroxidation\(^8\). This activation cascade is associated with the production of several inflammatory cytokines and promotes liver fibrosis\(^9\). TAA needs two steps for activation in the liver to yield a reactive metabolite. TAA is first converted into thioacetamide sulfur dioxide and then to thioacetamide sulfur dioxide via CYP450. The dioxide derivative is an unstable reactive metabolite, which initiates liver damage by a not yet fully understood mechanism. However, this derivative may bind to hepatocellular macromolecules, causing the upregulation of proteins related to lipid peroxidation and oxidative stress\(^10\). TAA does not inhibit the cytochrome P450 oxygenase system in contrast to CCl\(_4\) and other thionsulfur compounds. TAA also induces hepatocarcinogenesis by increasing the oxidative stress and decreasing the antioxidant enzyme function by sulfur dioxide\(^7\).

However, several questions should be answered: does hepcidin expression and thus blood levels change from model to model; does the inflammatory stimulus, namely, IL-6, play the same enhancing role in both models; and do the iron metabolic patterns and blood images differ accordingly between both models?

This study aims to compare blood profiles and iron indices [serum iron, unsaturated iron binding capacity (UIBC), total iron binding capacity (TIBC), transferrin saturation\%, and serum transferrin concentration] in CCL\(_4\) and TTA subchronic liver injuries by determining the underlying regulatory roles of hepcidin and cytokine IL-6.

**MATERIALS AND METHODS**

**Chemicals and Reagents**

CCl\(_4\) and TAA were purchased from Sigma-Aldrich, SL, USA via a local distributor. TIBC colorimetric reagent set was obtained from Pointe Scientific® Inc., MI, USA via a local distributor. Rat ferritin ELISA kit was acquired from Genway Biotec®, Inc., CA, USA, via a local distributor. RT-PCR Trizol reagent, Oligo (dT) primer, Superscript II reverse transcriptase, Taq DNA polymerase, hepcidin, IL-6, and β-actin primers were supplied by Invitrogen, Carlsbad, CA. All other chemicals were of analytical grade and available from local distributors.

**Animal Models and Study Design**

Thirty male albino rats aged 6 weeks and weighing 180-200 g were acclimatized under hygienic condition and given free access to clean water and balanced diet. The rats were then randomly separated into three groups (10 each group) in separate cages and subjected to different treatments. Subchronic liver injury/fibrosis was induced in groups 2 and 3 by repeated intraperitoneal injections of CCL\(_4\) (100 \(\mu\)L/100 g rat weight diluted as 1:4 in corn oil) or TTA (10 mg/100 g rat weight dissolved in isosaline) twice a week for 8 weeks (modified after Scholten et al.\(^{11}\) and Wallace et al.\(^{12}\), respectively). Control group (C) was injected with vehicles (corn oil and isosaline) at the same time. On the day after the last administration, blood samples were collected from the medial canthus venous plexus under light ether anesthesia. Two types of blood samples were saved. The first sample was received into EDTA tube for blood examination. The second sample was received into a plain sampling tube, left to coagulate, and centrifuged. Serum was harvested for determination of transaminases, iron, UIBC, and ferretin. After blood collection, the rats were sacrificed. The livers were removed, and pieces (100 mg) were submerged in Trizol reagent for RNA isolation and PCR. All procedures had ethical approval. The animals received daily human care, and the study protocols complied with our institutional guidelines. The study conformed to ARRIVE guidelines (http://www.nc3rs.
Serum Transferrin concentration was calculated from its correlation with TIBC, where one molecule of transferrin can bind to two molecules of iron at two high-affinity binding sites, by using the following equation according to previous works\textsuperscript{17-18}:

\[ \text{TIBC} (\mu\text{mol/L}) = 25.1 \times \text{transferrin} (\text{g/L}) \] (1)

where \((\mu\text{g/dL}) = 0.179 (\mu\text{mol/L})\) according to SI conversion.

**Ferritin Assay**

Ferritin, the iron storage protein, was determined by ELISA kit according to the instructions of the manufacturer. Ferritin in the serum samples reacted with anti-ferritin antibodies, which were adsorbed onto the surface of the polystyrene microtiter plate. After the removal of unbound proteins by washing, anti-ferritin antibodies conjugated with horseradish peroxidase (HRP) were added. These enzyme-labeled antibodies formed complexes with the previously bound ferritin. After another washing step, the enzyme bound to the immunosorbent was assayed by adding a chromogenic substrate, 3,3',5,5'-tetramethylbenzidine (TMB). The quantity of the bound enzyme varied directly with the concentration of ferritin in the sample tested. Absorbance was recorded using a microplate reader at 450 nm to measure the concentration of ferritin in the test sample.

**RT-PCR of Hepcidin and IL-6 in Hepatocytes**

Total cellular RNA was extracted from the hepatic specimens by Trizol reagent according to Chomczynski and Sacchi\textsuperscript{19}. In brief, 100 mg of each liver tissue specimen was homogenized in 1 mL of Trizol reagent by using a power homogenizer (IKA Labortechnik Staufen, Staufen, Germany). The homogenized samples were transferred to 1.5 mL Eppendorf tubes and added with 0.2 mL of chloroform for phase separation. After vigorous shaking for 15 s, the samples were centrifuged at 12,000 rpm and 4 °C for 15 min. The mixture separated into a lower red, phenol-chloroform phase, an inter-phase, and a colorless upper aqueous phase. RNA remained in the aqueous phase. For RNA precipitation, the aqueous phases were transferred to fresh tubes and added with 0.5 mL of isopropanol. The tubes were incubated at room temperature for 15 min and centrifuged again at 12,000 rpm for 15 min. The RNA precipitate, which is often invisible before centrifugation, formed a gel-like pellet on the side and bottom of the tube. The pellets were washed in 75% ethanol after removal of the
The washing alcohol solution was removed, and the pellets were left at room temperature for 10 min to dry up. The dried pellets were redissolved in RNase-free water according to the size of the pellet. RNA concentration was determined by recording their absorbance (A) at 260 and 280 nm with a spectrophotometer (the A260/280 values were less than 1.6 in all samples assuming no protein contamination). RNA samples were subjected directly to reverse transcription (RT).

RT was performed with RNA random primers by using RT-PCR kit (Takara Bio INC., Shiga, Japan) according to the instructions of the manufacturer. Aliquots of 2.5 µg of the isolated RNA in a suitable volume of RNase-free water (1-5 µL according to the concentration of RNA measured in the sample; preferred to be added lastly to avoid trans-contamination) were used for RT. The obtained first-strand complementary DNAs (cDNAs) were kept at -20 °C until PCR was performed.

PCR was performed using the same kit with rat hepcidin, IL-6, and β-actin primers prepared by nucleic acid synthesis system (Rikaken, Nagoya, Japan). The sense (forward) and antisense (reverse) sequences were 5′-GCC TGG ATG GCT AC and 5′-TGG AAG TTG GGG TA for hepcidin; 5′-TGA TGG ATG CTT CCA AAC TG and 5′-GAG CAT TGG AGG TGG TA for IL-6; and 5′-TGT CAC CAC GGA AGG TA and 5′-AAC ACA GCC TGG ATG GCT AC for β-actin.

The PCR products were size fractionated by 1.5% agarose gel electrophoresis starting with 70 V for 20 min and continuing with 120 V until aliquots reached the desired separation levels. The DNA bands were visualized with an ultraviolet trans-illuminator (UVP, CA, USA). Quantification of hepcidin, IL-6, and β-actin amplified DNAs was carried out by densitometric analysis using Scion Image 4.02 software (Scion Corporation, Maryland, USA), setting the control density as the unity and calculating hepatotoxins as folds.

### Data Presentation and Analysis

Data are expressed as mean ± standard error of the mean of 10 (control) or 9 (groups 2 and 3) separate observations. Observations were compared using ANOVA followed by LSD as post-hoc test at P level of 0.05. All procedures of statistics and graphing were completed using the computer program GraphPad Prism® version 6 (GraphPad Inc., CA, USA).

### RESULTS

Nine of 10 rats in groups 2 and 3 survived until the end of the experimental course. The subchronic TAA and CCL₄ treatments induced significant elevations of the liver enzymes, namely, AST and ALT, which indicated damage to liver cells. The values recorded after CCl₄ were lower than those recorded after TAA (Table 1).

The erythrocyte and leukocyte parameters and those of platelets were significantly (P > 0.05) altered after repeated subchronic hepatotoxin injections compared with those in the control group (Tables 2, 3, and 4). Table 2 shows the diminished erythrocyte count, Hb concentration, hematocrit value, and erythrocytic indices toward anemic condition in the CCl₄ model but not in the TAA model. Table 3 shows the data of leukogram, indicating significant leukocytosis with significant granulocytosis and insignificant lymphocytopenia. The altered leukogram was evident in both models. Table 4 shows that the platelets exhibited thrombocytopenia and decreased plateletcrit with insignificantly altered MPV index after subchronic treatment with both hepatotoxins and increased the PDW index only in the case of TTA. Thrombocytopenia was more drastic in the TAA model than in the CCl₄ model.

### Table 1. Transaminases as Liver Serum Biomarkers after Repeated i.p Injections of TAA and CCl₄ to Rats Compared to Those of Normal Control

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Weeks</th>
<th>Control</th>
<th>TAA</th>
<th>CCl₄</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALT (U/L)</td>
<td>8</td>
<td>23.87 ± 1.92</td>
<td>275.0 ± 14.3*</td>
<td>155.0 ± 11.3*</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td>8</td>
<td>29.53 ± 2.05</td>
<td>308.1 ± 18.9*</td>
<td>216.3 ± 12.6*</td>
</tr>
</tbody>
</table>

**Note.** *Means significantly (P < 0.05) different from corresponding control; TAA: thioactamide, 10 mg/100 g rat weight, dissolved in isosaline; CCl₄: carbon tetrachloride, 100 µL/100 g rat weight, diluted as 1:4 in corn oil; ALT: alanine aminotransferase; AST: aspartate aminotransferase. Mean ± SE, n = 9 for treated groups (twice weekly, for 8 weeks) and 10 for the control (isosaline/corn oil).
Serum analytical assays revealed significantly increased erythropoietin (EPO) concentration in the CCL4 group compared with that in the control and TAA group. The levels of serum iron, UIBC/TIBC, transferrin, and transferrin saturation% significantly decreased, and that of ferritin increased in the CCL4 group compared with those in the control rats. In the TAA model, the serum iron and iron indices changed toward iron overload, although this change was insignificant (Figure 1A-F).

RT-PCR analysis of the hepatic specimen revealed increased expression of hepcidin mRNA associated with increased expression of IL-6 mRNA in the CCL4 group. The TTA group showed unexpected significant decrease in hepcidin mRNA expression, and that of IL-6 did not significantly change (Figure 2A-B).

**DISCUSSION**

Anemia is one of the most common blood disorders caused by disturbance of iron metabolism.

### Table 2. Erythrocyte Parameters after Repeated i.p. Injections of TAA and CCl4 to Rats, Compared to that of Normal Control

<table>
<thead>
<tr>
<th>Erythrocyte Parameters</th>
<th>Control</th>
<th>TAA</th>
<th>CCl4</th>
</tr>
</thead>
<tbody>
<tr>
<td>RBC (10^12/L)</td>
<td>8.02 ± 0.31</td>
<td>7.12 ± 0.39</td>
<td>5.11 ± 0.34*</td>
</tr>
<tr>
<td>PCV (%)</td>
<td>46.81 ± 2.63</td>
<td>39.37 ± 3.95</td>
<td>26.02 ± 2.14*</td>
</tr>
<tr>
<td>HGB (g/dL)</td>
<td>15.21 ± 1.88</td>
<td>12.73 ± 0.82</td>
<td>8.21 ± 0.75*</td>
</tr>
<tr>
<td>MCV (FL)</td>
<td>58.35 ± 1.73</td>
<td>55.29 ± 3.11</td>
<td>50.91 ± 1.52*</td>
</tr>
<tr>
<td>MCH (pg)</td>
<td>18.97 ± 1.55</td>
<td>17.84 ± 1.15</td>
<td>16.07 ± 0.97</td>
</tr>
<tr>
<td>MCHC (g/dL)</td>
<td>32.51 ± 3.01</td>
<td>32.26 ± 2.25</td>
<td>31.56 ± 1.77</td>
</tr>
</tbody>
</table>

*Note. Mean significantly (P < 0.05) different from it; RBC: red blood count; PCV: packed cell volume; HGB: hemoglobin concentration; MCV: mean corpuscular volume; MCHC: mean corpuscular hemoglobin concentration; TAA: 10 mg/100 g rat weight dissolved in isosaline; CCl4: 100 μL/100 g rat weight diluted as 1:4 in corn oil. Mean ± SE, n = 9 for treated groups (twice weekly, for 8 weeks) and 10 for the control (isosaline/corn oil).*

### Table 3. Leukocyte Parameters after Repeated i.p. Injections of TAA and CCl4 to Rats, Compared to that of Normal Control

<table>
<thead>
<tr>
<th>Leukocyte Parameters</th>
<th>Control</th>
<th>TAA</th>
<th>CCl4</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC (10^9/L)</td>
<td>13.53 ± 2.43</td>
<td>21.13 ± 2.13*</td>
<td>26.33 ± 2.30*</td>
</tr>
<tr>
<td>Lymph. (%)</td>
<td>71.83 ± 3.53</td>
<td>67.41 ± 3.25</td>
<td>68.06 ± 3.19</td>
</tr>
<tr>
<td>Mid-sized (%)</td>
<td>2.44 ± 0.52</td>
<td>2.29 ± 0.23</td>
<td>3.07 ± 0.30</td>
</tr>
<tr>
<td>Gran. (%)</td>
<td>24.23 ± 0.75</td>
<td>30.38 ± 1.19*</td>
<td>29.41 ± 1.55*</td>
</tr>
</tbody>
</table>

*Note. Mean significantly (P < 0.05) different from it. WBC: white blood cell; Lymph: lymphocytes; Mid-sized: mid-sized cells; Gran: granulocytes; TAA: 10 mg/100 g rat weight dissolved in isosaline; CCl4: 100 μL/100 g rat weight diluted as 1:4 in corn oil. Mean ± SE, n = 9 for treated groups (twice weekly, for 8 weeks) and 10 for the control (isosaline/corn oil).*

### Table 4. Platelet Parameters after Repeated i.p. Injections of TAA and CCl4 to Rats, Compared to that of Normal Control

<table>
<thead>
<tr>
<th>Platelet Parameters</th>
<th>Control</th>
<th>TAA</th>
<th>CCl4</th>
</tr>
</thead>
<tbody>
<tr>
<td>PLT (10^9/L)</td>
<td>655.6 ± 17.44</td>
<td>388.8 ± 11.2*</td>
<td>442.6 ± 14.2*</td>
</tr>
<tr>
<td>PCT (%)</td>
<td>0.53 ± 0.02</td>
<td>0.36 ± 0.05*</td>
<td>0.45 ± 0.03*</td>
</tr>
<tr>
<td>MPV (FL)</td>
<td>9.13 ± 0.41</td>
<td>9.26 ± 0.26</td>
<td>10.17 ± 0.28</td>
</tr>
<tr>
<td>PDW (%)</td>
<td>16.38 ± 1.02</td>
<td>22.48 ± 1.06*</td>
<td>19.12 ± 1.11</td>
</tr>
</tbody>
</table>

*Note. Mean significantly (P < 0.05) different from it; PLT: platelet; PCT: procalcitonin; MPV: mean platelet volume; PDW: platelet distribution width; TAA: 10 mg/100 g rat weight dissolved in isosaline; CCl4: 100 μL/100 g rat weight diluted as 1:4 in corn oil. Mean ± SE, n = 9 for treated groups (twice weekly, for 8 weeks) and 10 for the control (isosaline/corn oil).*
Figure 1. Changes in erythropoietin (A), serum iron (B), ferritin (C), UIBC/TIBC (D), transferrin saturation% (E), and serum transferrin concentration (F) in rats after repeated (twice weekly, for 8 weeks) i.p. injection of TAA (10 mg/100 g rat weight dissolved in isosaline) and CCl₄ (100 μL/100 g rat weight diluted as 1:4 in corn oil) in comparison with normal rats (isosaline/corn oil); Mean ± SE, n = 9 for treated groups and 10 for the control. *P < 0.05.

Figure 2. RT-PCR products and fold analysis of liver hepcidin (A) and IL-6 (B) mRNA expression in rats after repeated (twice weekly, for 8 weeks) i.p. injections of TAA (10 mg/100 g rat weight dissolved in isosaline) and CCl₄ (100 μL/100 g rat weight diluted as 1:4 in corn oil) in comparison with normal rats (isosaline/corn oil); Mean ± SE of 3 observations; control value was set as the unit and those of hepatotoxins were set as folds. **P < 0.01.
either as deficiency or as overload. Relative iron deficiency anemia associated with inflammatory liver disease is attributed to induced expression of the hepcidin gene. Hepcidin regulates iron availability into the blood circulation via an iron transport protein, namely, ferroportin. Ferroportin is the only known cellular iron exporter in vertebrates[2]. Hepcidin binds to ferroportin and causes its internalization and degradation in lysosomes. The loss of ferroportin from the cell membrane ablates iron efflux from iron exporting tissues into plasma. In ferroportin-deficient animals, iron accumulates in enterocytes, macrophages, and hepatocytes, indicating the key role of ferroportin, particularly in these cells[20]. When the amounts of iron stored are high, the liver produces hepcidin and releases it to circulation. By binding to ferroportin and causing its internalization, hepcidin blocks the sole pathway for transfer of iron from enterocytes to plasma. When the amounts of iron stored are low, hepcidin synthesis is suppressed; ferroportin molecules are expressed on enterocyte basolateral membranes and absorb iron from the enterocyte cytoplasm to plasma transferrin. A similar pathway occurs in macrophages that recycle aged RBCs and in hepatocytes that store iron.

Liver fibrosis is a pathological sequel after repeated or sustained wound healing response to chronic injury caused by many factors, including, hepatitis virus, alcohol, infection, metabolic disorders, and hepatotoxic drugs[21]. At present, liver transplantation is the only available treatment for liver fibrosis and cirrhosis. However, this treatment is costly and has moderate prognosis (moderate possibility of cure), hampered by limited number of liver donors. Therefore, additional clinical strategies for liver fibrosis must be developed. Experimental models of liver fibrosis are a research must. Chemically induced models of liver inflammation and fibrosis obtained by repeated administrations of CCl₄ or TAA to rats and mice are extensively used because of their reproducibility and similarities to human liver fibrosis (can progress from a fibrotic stage into a cirrhotic stage or reverse the fibrotic process removal of the causative hepatotoxin)[22].

This study aimed to compare hemograms, iron homeostatic patterns, and underlying driving molecules, namely, hepcidin and IL-6, between two common models of liver fibrosis.

The establishment of liver fibrosis in both models was confirmed by elevation of liver transaminases (AST and ALT) that leaked to blood from the injured hepatocytes upon repeated administrations of either of hepatotoxins (Table 1). The values of both transaminases were markedly higher in the TAA model than those in the CCL₄ model. This finding indicates the higher capability of TAA as a fibrosis inducer compared with CCL₄, despite applying standardized doses of each hepatotoxin.

Repeated CCl₄ injections for 8 weeks (subchronic) significantly decreased the RBC count, PCV, Hb, and MCV values compared with the normal control; however, the rest of the blood indices were minimally affected (Table 2). These findings could be explained on the basis of the reduced responsiveness to EPO (although elevated, Figure 2A) in the presence of inflammatory mediators and markers, such as C-reactive protein, hepcidin, and IL-6, which antagonize the response to EPO[23]. In addition, iron must be available for erythroid precursors in the bone marrow for erythropoiesis. In the present study, the serum iron level decreased in the CCl₄ group compared with that in the control group (Figure 1B). This finding may be explained by the increased expression of hepcidin mRNA in the liver cells (Figure 2A) in the CCl₄ group. The increased expression was found to be stimulated by the inflammatory cytokine, IL-6 (Figure 2B). This finding is consistent with the statement of Besarab and Coyne[24], who reported that increased hepcidin production decreased the efflux of recycled iron from splenic and hepatic macrophages and the release of iron from storage in hepatocytes, leading to functional iron deficiency and inflamed liver anemia. Hepcidin also binds to enterocytes, causing poor absorption of dietary iron.

The TAA model did not show significant changes in the hemogram of the subchronically affected animals. This finding could be explained by the suppression of hepcidin mRNA expression with no significant inhibitory effects on iron; by contrast, the serum iron level increased. Hepcidin expression was associated with the non-elevation of the inflammatory cytokine IL-6 (Figure 2). Although the fibrotic effect of TAA, indicated by higher transaminase levels, was more powerful than that of CCL₄, it did not increase the hepcidin expression that is considered one of the positive inflammatory reactants. Moreover, EPO showed no significant changes in the TAA model.

Transferrin is a protein synthesized and released by the liver and is responsible for iron transport through the plasma. The expression of this protein
increases in absolute iron deficiency to maximize the utilization of the limited iron available\textsuperscript{25}. In inflammation, the ability of the diseased liver to synthesize proteins, including transferrin, is reduced. UIBC and TIBC could be alternative tests to transferrin. UIBC/TIBC and transferrin saturation% indicate the free iron binding sites on transferrin. These values increase in absolute iron deficiency but decrease in iron overload\textsuperscript{26}. However, in the present study, all of the values decreased, despite the recorded reduction of serum iron because of the reduced transferrin concentration (Figure 1D-F) under the induced inflammatory condition. Therefore, iron and iron indices are considered appropriate tools for accurate etiologic diagnosis of anemia associated with iron deficiency\textsuperscript{27}. Ferritin is an additional valuable test that differentiates between anemic conditions characterized by iron deficiency (whether absolute iron deficiency anemia or inflammatory anemia). Ferritin is the second major iron-containing protein after hemoglobin in the body. Unlike hemoglobin, ferritin acts only as iron storage and is found mainly in the cytoplasm of reticuloendothelial cells\textsuperscript{28} as well as in the liver, spleen, bone marrow, and serum. A direct correlation exists between serum ferritin and total iron storage in the body. For each 1 ng/mL of serum ferritin, 10 mg of iron is stored in tissues and organs\textsuperscript{29}. Decreased serum iron level and depleted ferritin under physiological levels is indicative of absolute iron deficiency anemia. However, decreased serum iron level and high ferritin in the context of decreased transferrin saturation is indicative of immune-driven iron sequestration in inflammation, infection, liver or kidney disease, and cancer\textsuperscript{30}. Consistent with this statement, the present study indicated that low serum iron, high ferritin, and low UIBC/TIBC and transferrin saturation% (Figure 1) confirmed the presence of inflammatory anemia rather than iron deficiency anemia.

The TAA model demonstrated relatively higher iron (although insignificant), ferritin, and transferrin saturation%, with insignificant changes in the transferrin concentration and UIBC/TIBC. This finding may be explained on the basis of reduced hepcidin production with consequent iron disturbance toward iron overload rather than iron deficiency.

In contrast to hemogram, leukogram exhibited similar findings in both liver injury models in the form of leukocytosis and granulocytosis (Table 3). These findings are in accordance with literature, in which inflammation/infection is associated with leukocytosis as defense mechanism of the body’s immune system.

Data of the platelet parameters showed thrombocytopenia and decreased plateletcrit value (Table 4). The findings may be explained on the basis of decreased thrombopoietin hormone production by the fibrotic liver\textsuperscript{31}.

**CONCLUSIONS**

The results show that although CCl\textsubscript{4} and TAA are chemical hepatotoxins, they may differ regarding their effect on hepcidin expression, hepatic IL-6 expression, iron indices, and anemia occurrence. Increased expression of hepcidin and IL-6 and inflammatory iron deficiency anemia were found only in the CCl\textsubscript{4} model but not in the TAA model. However, the effects on liver tissue (fibrosis), leukogram, and platelets are still parallel. These findings should be taken in consideration in diagnosis and therapeutics of liver disease and associated disturbed parameters.

**AUTHOR CONTRIBUTIONS**

Both authors contributed equally to this work, including in the concept and design, experiments and procedures, data analysis, and writing and revision of the article.

**CONFLICTS OF INTEREST STATEMENT**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The author(s) declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Received: December 23, 2018; Accepted: March 4, 2019

**REFERENCES**

